Physician profile
Reena Vanmali
NPI 1356607790
$2,985.18
in general payments reported to CMS, 2019-2025
24 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.21 · 2022: $165 · 2023: $872 · 2024: $925 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $494.00 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $446.27 | 2022-2025 | |
| Lilly USA, LLC | $340.95 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $299.51 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Dexcom, INC. | $177.45 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $155.80 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $152.74 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $149.28 | 2023-2025 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.66 | 2025 | Caplyta |
| Astellas Pharma US INC | $124.30 | 2024-2025 | Veozah |
| Pfizer INC. | $105.63 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $58.40 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.17 | 2024-2025 | Jardiance |
| Amgen INC. | $43.29 | 2023-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.95 | 2024-2025 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $34.22 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $31.08 | 2024-2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $28.90 | 2022 | |
| Organon LLC | $23.37 | 2023 | Nexplanon |
| Idorsia Pharmaceuticals US INC | $22.10 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $21.89 | 2023 | Vaxneuvance, Gardasil 9 |
| Antares Pharma, INC. | $21.18 | 2024 | Xyosted |
| Hologic Sales and Service, LLC | $20.28 | 2023 | Aptima, Thinprep 2000 Processor |
| Abbott Laboratories | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Vanmali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.